MBX Biosciences, Inc. — Form SCHEDULE 13D/A
Filed August 10, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 18/100
What the filing says
Multiple Frazier Life Sciences entities (Public Fund L.P., X L.P., XI L.P., and related management entities) and individuals James N. Topper and Patrick J. Heron jointly agreed on August 10, 2026, to file a single Schedule 13D statement under Rule 13d-1(k)(1) regarding their collective ownership of MBX Biosciences common stock. Jennifer Martin executed the agreement as CFO/attorney-in-fact. The filing specifies no new share counts, dollar amounts, or changes to existing positions.
Why this rating
Routine administrative coordination agreement for Schedule 13D reporting; no new ownership data or material transaction disclosed; standard procedural compliance.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.